Dostarlimab with carboplatin–paclitaxel for advanced or recurrent endometrial cancer in Chinese patients with dMMR/MSI-H

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

In this Phase 2 interventional study, Chinese participants with recurrent or primary advanced endometrial cancer and confirmed dMMR/MSI‑H tumors receive dostarlimab together with carboplatin and paclitaxel to measure tumor response, safety, pharmacokinetics, and immunogenicity. Eligibility requires histologic or cytologic confirmation, at least one measurable lesion per RECIST 1.1, and either being systemic-therapy naive or having a first recurrence at least six months after prior adjuvant/neoadjuvant therapy. dMMR/MSI‑H status is confirmed by a central reference laboratory and adequate archived tumor tissue must be available. Regular imaging and laboratory assessments will be used to track response and adverse events during treatment and follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Participant has histologically or cytologically proven EC with recurrent or advanced disease.
2. Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.
3. Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination, and presence of at least one target lesion per RECIST 1.1 based on Investigator's assessment and meet at least 1 of the following criteria:

   1. Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;
   2. Has first recurrent disease and is naïve to systemic anticancer therapy for EC;
   3. Had received prior neo-adjuvant/adjuvant anticancer therapy and had a recurrence or PD ≥6 months after completing treatment (first recurrence only).
4. Participant has adequate archive tumor tissue sample for MMR/MSI status testing. If no archival tissue is available, tissue sample must be obtained before study intervention.
5. Participant is not pregnant or breastfeeding and agrees to use a highly effective contraceptive method during the study period if a woman of childbearing potential (WOCBP).
6. Participant has an Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0 or 1.
7. Participant has adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters.

Exclusion Criteria:

1. Participant has a concomitant malignancy, or participant has a prior non-endometrial invasive malignancy who has been disease-free for \<3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
2. Participant has any medical history of interstitial lung disease or pneumonitis.
3. Participant has cirrhosis or current unstable liver or biliary disease.
4. Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.
5. Participant has a diagnosis of immunodeficiency.
6. Participant has received prior therapy with an anti- Programmed death protein 1 (PD-1), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.
7. Participant has not recovered adequately from AEs.
8. Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days prior to the first dose of study intervention.
9. Participant has received any live vaccine within 30 days of the first dose of study intervention. Vaccination against coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms are not exclusionary.
10. Participant has Hepatitis B surface antigen (HBsAg) positive, or Hepatitis C virus (HCV) Ribonucleic acid (RNA) positive at screening or within 3 months prior to the first dose of study intervention.
11. Participant is known human immunodeficiency virus (HIV) infection.
12. Participant is currently participating and receiving study intervention or has participated in a study of an investigational agent and received study intervention or used an investigational device within 4 weeks of the first dose of treatment.
13. Participant with contraindication to carboplatin and paclitaxel.

Where it's running

• GSK Investigational Site
  Jinan, Shandong, China Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Maintenance mocertatug rezetecan with immune therapy for endometrial cancer

  This study tests whether adding Mocertatug Rezetecan to the physician’s chosen immunotherapy helps people with advanced or recurrent endometrial cancer stay on maintenance treatment longer.

  Recruiting at 12 sites Phase 3 GlaxoSmithKline · Toronto, Ontario and 11 other locations · NCT07684599

• Testing a B7‑H3 antibody–drug conjugate alone and with dostarlimab in recurrent/metastatic head and neck squamous cell carcinoma

  It tests an antibody–drug conjugate called GSK5764227 by itself or with the immunotherapy dostarlimab in adults with recurrent or metastatic head and neck squamous cell carcinoma who have received prior treatments.

  Recruiting Phase 2 University Health Network, Toronto · Toronto, Ontario · NCT07408063

• Dostarlimab with cisplatin, etoposide, and radiotherapy for small cell neuroendocrine cervical cancer

  This trial will test whether adding the immunotherapy drug dostarlimab to cisplatin/etoposide chemotherapy plus radiotherapy helps women with small cell neuroendocrine cervical carcinoma stay progression-free longer.

  Recruiting Phase 2 Chang Gung Memorial Hospital · Taoyuan, Taiwan · NCT07336147

• Mo-Rez vs chemotherapy for endometrial cancer after platinum-based therapy

  In people with endometrial cancer who have already had platinum therapy, this study tests mocertatug rezetecan (Mo-Rez) against standard chemotherapy to see how well it works and how safe it is.

  Recruiting at 56 sites Phase 3 GlaxoSmithKline · Birmingham, Alabama and 55 other locations · NCT07286331

• Neoadjuvant dostarlimab for locally advanced dMMR/MSI‑H rectal cancer in routine practice

  This project will try neoadjuvant dostarlimab in adults with dMMR/MSI‑H stage II–III rectal cancer to see how well it works and how safe it is in real-world clinical care.

  Recruiting National Cancer Institute, Naples · Naples and 1 other locations · NCT07269249

• Neoadjuvant dostarlimab before surgery for resectable stage III pMMR/MSS colon cancer

  This will test whether two pre-surgery infusions of the PD-1 drug dostarlimab help people with resectable stage III pMMR/MSS colon cancer.

  Recruiting Phase 2 Universitaire Ziekenhuizen KU Leuven · Leuven · NCT06830239

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.